Download Your Complimentary Copy of the Agenda
The 7th RAS-Targeted Drug Development Summit is your unique forum to learn and network with the brightest minds revolutionising the industry.
Having trouble downloading the brochure? Let us know and we’ll email it to you instead.
Join Us to Drive Robust & Durable Cancer Treatments Towards Approval
Uniting key stakeholders from the likes of Pfizer, Amgen, Bristol Myers Squibb, PAQ Therapeutics, Revolution Medicines, Affini-T Therapeutics and more, this is your opportunity to take part in 3-days dedicated to addressing key challenges in resistance, tolerability and biomarker strategies for driving more efficacious RAS medicines towards the patients in need.
What to Expect?
120+
Attendees from Large Pharma, Biotech & Academia
35+
World-Class Speakers
30+
Data-Driven Presentations
8+
Hours of Dedicated Networking
7+
Deep-Dive Discussions
Hear What Our Past Attendees Have to Say
A wonderful opportunity to participate in a comprehensive RAS focused conference with diverse coverage of multiple approaches (SMIs & biologics) that target RAS with the end game to expeditiously deliver novel therapies to patients.
Michael Niedbala, Executive Director, Early Oncology Projects, AstraZenecaFirst
This summit is one of the few and best forums focusing on RAS-targeting drugs for industry leaders and researchers. It is extremely helpful as several classes of KRAS inhibitors and degraders are in clinical development.
Huaixiang Hao,Vice President, Head, Research, PAQ Therapeutics